Breast Cancer Treatment in India
Get Breast Cancer Treatment at internationally accredited (JCI/NABH) Indian hospitals at a fraction of Western costs, with end-to-end international patient support — visa, travel, stay, and follow-up care.
Breast Cancer Treatment in UAE
Breast Cancer Treatment at leading UAE hospitals in Dubai and Abu Dhabi — world-class care closer to home, visa-free entry for many nationalities, international specialists, and modern facilities.
Overview
Breast cancer treatment encompasses a multidisciplinary spectrum of interventions — from breast-conserving lumpectomy and mastectomy to targeted biological therapy, immunotherapy, and stereotactic radiotherapy — achieving 5-year survival rates exceeding 90% for early-stage disease when delivered at high-volume oncology centers. International patients increasingly choose India and the UAE for breast cancer care, drawn by world-class oncology infrastructure, sub-wait-time access to cutting-edge diagnostics, and costs that are a fraction of those in Western countries. GAF Healthcare connects patients directly with JCI- and NABH-accredited institutions in India and JCI- and DHA-licensed centers in Dubai and Abu Dhabi, providing end-to-end coordination from the first remote consultation through post-treatment follow-up.
Hospital Stay: 3–10 days (varies by modality: lumpectomy 1–3 days; mastectomy with reconstruction 5–10 days; chemotherapy cycles administered as day-care or short inpatient admissions) • Total Stay in Country (Fit-to-Fly): 2–6 weeks (2–3 weeks post-lumpectomy; 4–6 weeks post-mastectomy with reconstruction; chemotherapy patients typically remain in-country for the full induction cycle before clearance to fly) • Success Rate: 90–95% (5-year overall survival for Stage I–II; approximately 72–80% for Stage III with multimodal therapy at specialist centers)
What Is It?
Breast cancer arises from malignant transformation of epithelial cells lining the mammary ducts (ductal carcinoma, comprising ~80% of cases) or lobules (lobular carcinoma). At the molecular level, tumors are stratified by receptor status — Estrogen Receptor (ER), Progesterone Receptor (PR), and Human Epidermal Growth Factor Receptor 2 (HER2) — as well as by genomic subtypes (Luminal A, Luminal B, HER2-enriched, Triple-Negative), each carrying distinct prognostic implications and dictating entirely different therapeutic algorithms. Locally advanced and metastatic disease may involve lymphovascular invasion, axillary node involvement, or distant spread to bone, lung, liver, or brain, requiring systemic therapy in addition to locoregional control.
The physiological burden of breast cancer extends beyond the primary tumor. Axillary lymph node involvement disrupts regional lymphatic drainage, predisposing patients to chronic lymphedema; HER2-positive subtypes and certain chemotherapy regimens (anthracyclines, trastuzumab) carry cardiotoxicity risk requiring baseline and serial echocardiographic surveillance; and endocrine therapy (aromatase inhibitors, tamoxifen) produces systemic hormonal effects including bone density loss and vasomotor symptoms that demand long-term management. Multidisciplinary Tumor Boards — comprising surgical oncologists, medical oncologists, radiation oncologists, pathologists, radiologists, and reconstructive surgeons — are therefore the global standard of care for all but the most straightforward early-stage presentations.
Modern standard of care integrates neoadjuvant chemotherapy (administered before surgery to downstage tumors and assess in-vivo chemosensitivity), precision surgery, adjuvant systemic therapy, and advanced radiotherapy. Genomic profiling tools such as Oncotype DX (21-gene Recurrence Score), MammaPrint (70-gene assay), and Prosigna guide decisions about adjuvant chemotherapy in hormone-receptor-positive, HER2-negative, node-negative or low-node disease, sparing many patients unnecessary systemic toxicity. Leading oncology centers in India and the UAE routinely deploy all of these technologies, offering care benchmarked against NCCN and ESMO guidelines.
Candidates
• ELIGIBLE PATIENTS:
• Women and men with histologically confirmed breast carcinoma (core-needle biopsy or excision biopsy with immunohistochemistry confirming ER/PR/HER2 status)
• Patients across all clinical stages (Stage I–IV) seeking definitive treatment, second opinions, or continuation of systemic therapy
• Patients with locally recurrent breast cancer after prior treatment
• High-risk individuals (BRCA1/BRCA2 pathogenic variants, strong family history) seeking risk-reducing prophylactic mastectomy
• Patients previously treated abroad seeking reconstructive surgery (implant-based, TRAM flap, DIEP flap, latissimus dorsi flap)
• Patients seeking fertility preservation consultation before gonadotoxic chemotherapy
• REQUIRED PRE-TREATMENT DIAGNOSTICS (to be arranged before travel or immediately upon arrival):
• Digital mammography and/or breast MRI (with contrast) for local staging and contralateral assessment
• Core-needle biopsy with full immunohistochemistry panel (ER, PR, HER2 by IHC and FISH/CISH, Ki-67 proliferation index)
• Genomic profiling (Oncotype DX, MammaPrint) where clinically indicated for hormone receptor-positive, HER2-negative disease
• Axillary ultrasound ± ultrasound-guided lymph node biopsy
• PET-CT scan (18F-FDG) for Stage II–IV disease to detect nodal and distant metastases
• CT scan of chest, abdomen, and pelvis for systemic staging
• Bone scan (or sodium fluoride PET) for suspected skeletal involvement
• Baseline ECHO (echocardiogram) or MUGA scan — mandatory before anthracycline or trastuzumab-based regimens
• Complete blood count (CBC), comprehensive metabolic panel, LFTs, tumor markers (CA 15-3, CEA)
• Genetic counseling and BRCA1/2 testing where indicated (strong family history, triple-negative subtype under 60 years)
• RELATIVE CONTRAINDICATIONS / SPECIAL CONSIDERATIONS:
• Active serious comorbidities (uncontrolled cardiac failure, NYHA Class III–IV) requiring optimization before surgery or chemotherapy
• Active pregnancy (requires specialized multidisciplinary management; surgery generally feasible in 2nd trimester; certain systemic agents contraindicated)
• Severe coagulopathy not correctable prior to surgery
• Prior chest-wall radiation limiting further radiotherapy options (requires Radiation Oncologist review)
• Patients on active anticoagulation therapy requiring bridging protocols
Procedure
SURGICAL APPROACHES:
1. Breast-Conserving Surgery (BCS / Lumpectomy with Oncoplastic Techniques): Removal of the tumor with clear surgical margins (minimum 2 mm for invasive carcinoma, no ink on tumor for DCIS per SSO-ASTRO guidelines) combined with oncoplastic volume displacement or replacement techniques to maintain breast aesthetics. Sentinel lymph node biopsy (SLNB) using dual-tracer technique (Technetium-99m radiocolloid + Patent Blue V dye, or increasingly indocyanine green fluorescence-guided) has replaced routine axillary lymph node dissection (ALND) in clinically node-negative patients, dramatically reducing lymphedema rates. BCS is invariably followed by adjuvant whole-breast irradiation.
2. Nipple-Sparing Mastectomy (NSM) and Skin-Sparing Mastectomy (SSM): Gold-standard procedures for patients requiring total mastectomy, particularly those seeking immediate reconstruction. Preservation of the nipple-areola complex (NAC) is oncologically safe in appropriately selected patients (tumor >2 cm from NAC, no Paget's disease, negative sub-areolar margin on frozen section). Robotic-assisted nipple-sparing mastectomy (using the da Vinci Xi system) is now offered at select centers in India (Tata Memorial, Apollo, Medanta) and the UAE (Cleveland Clinic Abu Dhabi, Mediclinic City Hospital), enabling smaller incisions, enhanced 3D visualization, and reduced skin flap trauma.
3. Modified Radical Mastectomy (MRM): Removal of the entire breast with overlying skin plus Level I–II axillary lymph node dissection. Indicated for locally advanced disease, inflammatory breast cancer, or when immediate reconstruction is not feasible.
4. Immediate Breast Reconstruction: - Implant-based reconstruction: Single-stage (pre-pectoral direct-to-implant with ADM — Acellular Dermal Matrix such as AlloDerm or Braxon) or two-stage (tissue expander followed by permanent implant) - Autologous reconstruction: DIEP flap (Deep Inferior Epigastric Perforator — gold standard, no muscle sacrifice, uses perforator-based microsurgery); TRAM flap (Transverse Rectus Abdominis Myocutaneous); Latissimus Dorsi flap; SIEA flap. Microsurgical free-flap reconstruction with perforator imaging (CT angiography) is routinely performed at high-volume centers in both destinations.
SYSTEMIC THERAPY:
5. Neoadjuvant and Adjuvant Chemotherapy: Anthracycline-taxane based regimens remain the backbone (AC-T: doxorubicin + cyclophosphamide followed by paclitaxel or docetaxel; dose-dense scheduling with G-CSF support reduces cycle intervals from 3 weeks to 2 weeks, improving pCR rates). For HER2-positive disease, dual anti-HER2 blockade with trastuzumab + pertuzumab concurrent with taxane-based chemotherapy (TCHP regimen) achieves pathological complete response (pCR) rates of 45–65%.
6. Targeted Biological Therapy: - HER2-positive: Trastuzumab (Herceptin), Pertuzumab (Perjeta), Trastuzumab emtansine (T-DM1, Kadcyla) for residual disease post-neoadjuvant therapy, Trastuzumab deruxtecan (T-DXd, Enhertu) for metastatic HER2-positive/low disease - CDK4/6 Inhibitors (Palbociclib, Ribociclib, Abemaciclib) + aromatase inhibitors: Standard of care for ER-positive, HER2-negative advanced/metastatic disease; Abemaciclib also approved adjuvantly in high-risk early-stage disease (monarchE trial) - PI3K Inhibitors: Alpelisib (Piqray) + fulvestrant for PIK3CA-mutated, ER-positive metastatic disease - PARP Inhibitors: Olaparib, Talazoparib for germline BRCA1/2-mutated HER2-negative metastatic breast cancer
7. Immunotherapy: Pembrolizumab (Keytruda) in combination with chemotherapy is approved for triple-negative breast cancer (TNBC) — both early-stage (KEYNOTE-522) and metastatic PD-L1-positive disease (KEYNOTE-355). Atezolizumab + nab-paclitaxel for PD-L1-positive TNBC.
8. Antibody-Drug Conjugates (ADCs): Sacituzumab govitecan (Trodelvy) for metastatic TNBC; Trastuzumab deruxtecan (T-DXd) for HER2-low (IHC 1+ or 2+/ISH-negative) metastatic breast cancer — a paradigm-shifting indication expanding the HER2-targetable population.
9. Endocrine / Hormonal Therapy: - Premenopausal: Tamoxifen ± ovarian function suppression (OFS) with GnRH agonists (goserelin/leuprolide); OFS + aromatase inhibitor (exemestane or letrozole) for high-risk premenopausal patients (SOFT/TEXT trials) - Postmenopausal: Third-generation aromatase inhibitors (anastrozole, letrozole, exemestane) as first-line adjuvant; Fulvestrant (selective estrogen receptor degrader) for advanced disease - Extended adjuvant therapy: 10 years of tamoxifen or switch strategies reduce late recurrence risk in ER-positive disease
RADIOTHERAPY:
10. Advanced Radiation Modalities: - Intensity-Modulated Radiation Therapy (IMRT) and Volumetric Modulated Arc Therapy (VMAT): Highly conformal whole-breast or chest-wall irradiation with cardiac and pulmonary dose-sparing, especially critical for left-sided tumors - Hypofractionated Whole-Breast Irradiation: 40 Gy in 15 fractions (FAST-Forward protocol: 26 Gy in 5 fractions over 1 week) — comparable efficacy to conventional fractionation with significantly reduced treatment duration, ideal for international patients - Deep-Inspiration Breath-Hold (DIBH) technique: Displaces the heart posteriorly during radiation delivery, reducing mean cardiac dose by up to 50% — standard for left-sided breast irradiation at leading centers - Intraoperative Radiotherapy (IORT — TARGIT or Electron-IORT): Single-fraction radiation delivered directly to the tumor bed at the time of lumpectomy; eliminates the need for an extended external beam radiotherapy course - Stereotactic Body Radiotherapy (SBRT): Used for oligometastatic disease (bone, lung, liver metastases) - Proton Therapy: Available at select centers in India (Apollo Proton Cancer Centre, Chennai) for complex cases requiring maximal cardiac and pulmonary sparing
Cost of Breast Cancer Treatment: India vs. UAE
The cost of breast cancer treatment varies substantially depending on the clinical stage, surgical complexity, chosen reconstruction technique, systemic therapy regimen, and whether radiotherapy is included. Both India and the UAE offer internationally benchmarked, high-quality oncology care at costs far below those in the United States, United Kingdom, or Western Europe — with India typically 50–70% less expensive than the UAE, and the UAE offering a premium environment, Arabic-language services, and minimal travel distance for Middle Eastern and African patients. The figures below represent all-inclusive estimates for the complete primary treatment episode (diagnosis-to-discharge); long-term adjuvant therapy (12–24 months of trastuzumab, 5–10 years of endocrine therapy, or multiple chemotherapy cycles) will be additional and should be discussed during your consultation with the GAF Healthcare case management team.
| Destination | Estimated Cost (USD) | Key Advantage |
|---|---|---|
| India | $4,000 – $22,000 | ~53% less than the UAE |
| UAE (Dubai/Abu Dhabi) | $10,000 – $45,000 | Premium care, JCI/DHA accredited |
Estimates typically include surgery, hospital stay, and standard medications. Contact us for a personalised quote.
Recovery & Aftercare
PHASE 1 — PRE-ARRIVAL & REMOTE CONSULTATION (2–4 Weeks Before Travel):
• Patient submits existing biopsy reports, imaging (mammogram, MRI, PET-CT), and blood work to GAF Healthcare's oncology case management team
• GAF Healthcare facilitates a secured video consultation with the treating surgical oncologist, medical oncologist, and reconstructive surgeon at the chosen destination
• Multidisciplinary Tumor Board review is conducted; a personalized treatment plan with staging, modality sequence, and timeline is prepared
• GAF Healthcare assists with e-Medical Visa application (India) or UAE entry documentation; all hospital appointment scheduling and pre-admission paperwork completed remotely
• Patient arranges travel insurance with oncology treatment coverage as advised by GAF
PHASE 2 — ARRIVAL & PRE-TREATMENT WORKUP (Days 1–5):
• Day 1: Airport pickup by GAF-arranged private transfer; check-in to GAF-partner accommodation adjacent to the hospital
• Days 1–2: Baseline diagnostics if not already completed or requiring local repeat — breast MRI with contrast, PET-CT, ECHO, complete labs, anesthesia assessment
• Day 2–3: Final surgical oncology, medical oncology, and reconstructive surgery consultations; informed consent; pre-operative marking and photodocumentation
• Day 3–5: Dedicated genetic counselor session (if BRCA testing indicated); fertility preservation consultation (if pre-chemotherapy oocyte/embryo cryopreservation is desired); pre-operative optimization including iron supplementation, cardiac clearance, anticoagulation management
PHASE 3 — PRIMARY TREATMENT (Surgery or Initiation of Neoadjuvant Chemotherapy):
SURGICAL PATHWAY (Days 5–10 approximately):
• Day of Surgery: General anesthesia induction; dual-tracer sentinel lymph node mapping injection (in nuclear medicine suite, ~2 hours pre-operatively); intraoperative frozen-section analysis of sentinel nodes and surgical margins; primary resection (BCS or mastectomy); simultaneous or immediate-delayed reconstruction if planned
• Post-operative Day 1: Drain management, pain control (multimodal analgesia protocol — regional nerve blocks, NSAIDs, acetaminophen, minimizing opioid use), upper extremity gentle mobilization exercises initiated by physiotherapy
• Post-operative Days 2–3 (BCS) or Days 4–7 (mastectomy ± reconstruction): Drain removal when output <30 mL/24h; wound inspection; final pathology review including surgical margins, lymphovascular invasion, Ki-67, and receptor status on excised specimen
• Final Pathology Multidisciplinary Review: Recommendation for adjuvant therapy (chemotherapy, radiotherapy, targeted therapy, endocrine therapy) delivered to patient before departure, with written care summary for home oncologist
NEOADJUVANT CHEMOTHERAPY PATHWAY (For Locally Advanced Disease — Remaining In-Country for First Cycle):
• Cycles administered at 14- or 21-day intervals; typically first 1–2 cycles delivered in-country to assess tolerability and manage acute toxicity (febrile neutropenia, nausea, mucositis)
• Concurrent anti-HER2 therapy initiated with first cycle where indicated
• ECHO repeated after 3 months of anthracycline therapy and after 6 months on trastuzumab
PHASE 4 — EARLY RECOVERY & PHYSIOTHERAPY (Weeks 2–4 In-Country):
• Daily physiotherapy: Progressive shoulder and arm mobilization to prevent axillary web syndrome (cording) and preserve range of motion; manual lymphatic drainage instruction
• Scar management: Silicone sheeting or gel application protocol initiated once wound healed
• Drain site monitoring; expander inflation session (if tissue expander placed) at 1–2 weeks post-op
• Oncology review appointment: Final adjuvant plan confirmed; prescriptions and treatment summary issued
• Patient education: Lymphedema prevention, arm care, signs of infection, long-term endocrine therapy instructions
PHASE 5 — FIT-TO-FLY CLEARANCE & DISCHARGE (Weeks 3–6 Depending on Modality):
• Post-lumpectomy: Fit-to-fly clearance typically at 2–3 weeks, subject to wound healing and drain removal
• Post-mastectomy with reconstruction: Fit-to-fly clearance at 4–6 weeks; economy-class seating with regular ambulation; compression garment for affected arm
• GAF Healthcare provides the patient with a comprehensive discharge dossier: operative report, final pathology, imaging on CD/USB, adjuvant therapy plan, emergency contact details for the treating oncologist, and a structured handover letter for the home oncologist
• Follow-up consultations arranged via GAF's telemedicine platform at 6 weeks, 3 months, and 6 months post-treatment
Risks & Considerations
Breast cancer treatment, while highly effective at accredited oncology centers, carries a defined spectrum of procedure-specific and therapy-specific risks that all patients must understand before committing to a treatment plan.
Surgical risks include seroma formation (the most common complication post-mastectomy, occurring in 15–85% of cases depending on surgical technique, typically managed with aspiration), wound infection, skin flap necrosis (particularly relevant in nipple-sparing mastectomy and immediate implant reconstruction), implant-related complications (capsular contracture in 5–30% at 10 years, implant rupture, implant malposition, BIA-ALCL — Breast Implant-Associated Anaplastic Large Cell Lymphoma, a rare but recognized FDA-acknowledged risk associated with textured implants), and microsurgical free-flap failure (partial or total flap loss in <5% of cases at experienced centers). Axillary lymph node dissection carries a lifetime risk of lymphedema of 15–25%, compared to <7% after sentinel lymph node biopsy alone.
Top Hospitals for Breast Cancer Treatment
The following JCI and NABH-accredited hospitals are among the most experienced in specialist care, with dedicated teams and high-volume programmes.
Apollo Hospitals
New Delhi, India
Medanta - The Medicity
Gurgaon, India
Kokilaben Dhirubhai Ambani Hospital
Mumbai, India
Tata Memorial Hospital
Mumbai, India
Top Doctors for Breast Cancer Treatment
Internationally trained specialists in Cancer Care. Review their profiles, compare experience, and connect directly through GAF Healthcare.
Dr. Kanchan Kaur
MBBS, MS (General Surgery), MRCS
Surgical Oncologist (Breast)
Medanta - The Medicity, Gurgaon, India
22+ Yearsof experience
Dr. Kanchan Kaur is a senior breast cancer and general surgeon who serves as Senior Director — Breast Cancer at the Cancer Care division of Medanta – The Medicity, Gurgaon. With more than two decades of surgical experience, she has built a multidisciplinary breast practice that combines oncologic clarity with deep patient empathy. Dr. Kanchan is widely respected for her work in breast cancer awareness and early detection. She works closely with several… Read more
Dr. Swathi Prakash
MCh, MS, MBBS
Breast Surgical Oncologist
Rela Hospital, Chennai, India
15+ Yearsof experience
Dr. Swathi Prakash is a Consultant in Breast Surgery and Surgical Oncology at Rela Hospital in Chennai, with over 15 years of clinical experience. She holds an MCh in Breast & Endocrine Surgery from All India Institute of Medical Sciences (AIIMS), New Delhi, and was the first in Tamil Nadu to achieve this distinction in breast surgery. Her comprehensive training encompasses both benign and malignant breast disease management, underpinned by rigorous… Read more
Dr. Deepak Jha
MBBS, MS (General Surgery), Fellowship in Surgical Oncology, Fellowship in Breast Surgery, FHNOS, Fellowship in Breast Surgery & Oncoplasty
Breast Surgical Oncologist
Artemis Hospital, Gurgaon, India
30+ Yearsof experience
Dr. Deepak Jha is Chief of Breast Surgery and Senior Consultant in Surgical Oncology at Artemis Hospital, Gurgaon, bringing 30 years of dedicated expertise in breast surgical oncology. He holds advanced fellowships from the European Board of Surgery and the European Society of Surgical Oncology, and trained in Surgical Oncology at AIIMS—making him among the first surgeons in India to earn formal European certification in breast surgery. His clinical depth… Read more
Dr. Geeta Kadayaprath
MBBS, MS, FRCS, MCh
Breast Surgical Oncologist
Apollo Athenaa Women's Cancer Centre, New Delhi, India
30+ Yearsof experience
Dr. Geeta Kadayaprath is a Senior Consultant Breast Surgical Oncologist with over 30 years of dedicated experience in breast cancer care and surgical oncology. She holds MBBS from Lady Hardinge Medical College, MS in General Surgery from Maulana Azad Medical College, FRCS (Fellow of the Royal College of Surgeons), and MCh in Oncoplasty from the University of East Anglia, reflecting rigorous surgical training and international exposure. Her qualifications… Read more
Dr. Siddhartha Chakravarthy
MCh, MS, MBBS
Surgical Oncologist & Breast Onco-Surgeon
Apollo Hospital, Jubilee Hills, Hyderabad, India
15+ Yearsof experience
Dr. Siddhartha Chakravarthy is a Consultant Surgical Oncologist and Breast Onco-Surgeon at Apollo Hospital, Jubilee Hills, Hyderabad, with over 15 years of specialized experience in surgical cancer care. He holds an MCh in Surgical Oncology and an MS in General Surgery from Christian Medical College (CMC), Vellore, one of India's most respected medical institutions. His clinical expertise is built on rigorous postgraduate training and a strong foundation… Read more
Frequently Asked Questions — Breast Cancer Treatment
The total cost of breast cancer treatment — encompassing diagnosis, primary surgery, hospital stay, pathology, and initial systemic therapy — ranges from approximately $4,000 to $22,000 USD in India, depending on the surgical approach (lumpectomy vs. mastectomy with free-flap reconstruction), the specific chemotherapy or targeted therapy regimen (e.g., a single chemotherapy cycle vs. a full neoadjuvant course plus adjuvant trastuzumab), and the tier of hospital chosen (NABH-accredited government cancer centers vs. JCI-accredited private hospitals such as Tata Memorial, Apollo, or Fortis). In the UAE (Dubai and Abu Dhabi), the equivalent treatment at JCI-accredited and DHA-licensed institutions such as Cleveland Clinic Abu Dhabi, Mediclinic City Hospital, or American Hospital Dubai typically costs between $10,000 and $45,000 USD, reflecting higher facility overheads, imported consumables, and premium hospitality standards. India is generally 50–70% less expensive than the UAE for equivalent oncological care, making it the preferred destination for cost-conscious patients from Africa, South Asia, and CIS countries, while the UAE attracts patients from the Middle East, GCC, and East Africa who prioritize proximity, Arabic-language services, and luxury-tier facilities. Long-term adjuvant therapies (12 months of trastuzumab, 5–10 years of endocrine therapy) are priced separately and will be outlined in the individualized treatment plan provided after your remote consultation with GAF Healthcare. Both destinations offer significantly lower costs than equivalent treatment in the United States ($100,000–$300,000+) or the United Kingdom ($50,000–$150,000+).
The minimum in-country stay before receiving fit-to-fly medical clearance depends directly on the treatment modality received. For breast-conserving surgery (lumpectomy with or without sentinel lymph node biopsy): a minimum of 14–21 days is recommended, allowing sufficient time for wound healing, drain removal (if a drain was placed), final pathology review, adjuvant therapy planning, and a physiotherapy assessment to ensure adequate shoulder range of motion. For mastectomy with immediate implant-based reconstruction: 3–4 weeks is typically required. For mastectomy with autologous microsurgical reconstruction (DIEP or TRAM flap): 4–6 weeks is standard, as the microvascular anastomosis requires close early monitoring and flap perfusion assessment before the patient is considered safe for long-haul travel. For patients commencing neoadjuvant chemotherapy: the first 1–2 treatment cycles (covering 3–6 weeks) are typically administered in-country to monitor for acute toxicity and confirm tolerability; subsequent cycles may be administered by the patient's home oncologist under a GAF-coordinated shared-care protocol. Regardless of modality, all patients are advised to travel in economy-plus or business class seating with an aisle seat to permit regular ambulation, wear appropriately fitted compression stockings on the affected arm (if axillary surgery was performed), maintain adequate hydration, and carry a copy of their discharge summary and emergency oncologist contact details. LMWH (low-molecular-weight heparin) prophylaxis for DVT prevention during long-haul flights is prescribed at the discretion of the treating oncologist and clearly documented in the patient's discharge plan prepared by GAF Healthcare.
Survival outcomes for breast cancer are strongly stage-dependent and must be interpreted in the context of tumor biology, molecular subtype, and the completeness of multimodal treatment received. At the high-volume, JCI- and NABH/DHA-accredited oncology centers affiliated with GAF Healthcare in India and the UAE — which collectively treat thousands of breast cancer cases annually and follow NCCN and ESMO guidelines — the following evidence-based benchmarks apply: Stage I breast cancer achieves 5-year overall survival rates of 99–100%; Stage II approximately 90–95%; Stage III approximately 72–80% with optimized multimodal therapy (neoadjuvant chemotherapy, surgery, adjuvant targeted therapy, and radiotherapy); Stage IV (metastatic) disease has a median overall survival that has improved dramatically with modern agents, reaching 3–5+ years for HER2-positive disease treated with pertuzumab-trastuzumab-taxane combinations, and 6–8+ years for ER-positive disease with CDK4/6 inhibitor-based regimens in selected patients. Pathological complete response (pCR) — the absence of residual invasive cancer in the breast and axillary nodes at the time of surgery after neoadjuvant therapy — is achieved in 45–65% of HER2-positive patients treated with TCHP (trastuzumab + pertuzumab + docetaxel + carboplatin) and 40–60% of triple-negative patients treated with anthracycline-taxane chemotherapy plus pembrolizumab (KEYNOTE-522 regimen), and pCR is a validated surrogate for improved event-free and overall survival. These outcomes are comparable to those reported by NCI-designated cancer centers in the United States. Your individualized prognosis will be discussed in detail during your Multidisciplinary Tumor Board review, which GAF Healthcare facilitates before you travel.
Why Plan Your Treatment Through Gaf Healthcare?
GAF Healthcare provides fully managed, concierge-level logistical support designed specifically for international oncology patients, recognizing that navigating a serious cancer diagnosis abroad requires far more than clinical excellence alone.
VISA & ENTRY DOCUMENTATION:
• India: GAF Healthcare's visa coordination team guides patients and one accompanying attendant through the Indian e-Medical Visa application process (available to citizens of 156+ countries), which permits stays of up to 60 days extendable to 180 days. We prepare the mandatory hospital invitation letter, confirm admission dates for submission, and advise on the supporting financial and travel documentation required by the Indian High Commission or Consulate.
• UAE (Dubai / Abu Dhabi): Citizens of GCC countries and most Western nations enjoy visa-free access or visa-on-arrival to the UAE. For patients from other regions, GAF Healthcare coordinates Patient (Medical) Visa applications through the General Directorate of Residency and Foreigners Affairs (GDRFA-Dubai) or MOHAP (Ministry of Health and Prevention) medical visa pathway, including the required hospital guarantee letter from our UAE-accredited partner institutions.
AIRPORT & GROUND TRANSFERS:
• Private, climate-controlled vehicle transfers from arrival airport to hospital and/or accommodation, with a GAF Healthcare patient liaison present to greet the patient — eliminating the stress of navigating an unfamiliar city upon arrival
• All subsequent inter-facility transfers (e.g., between diagnostic center and hospital, or hospital to rehabilitation facility) are coordinated and pre-booked
• Wheelchair assistance and medical escort services arranged on request for patients with limited mobility
ACCOMMODATION:
• GAF Healthcare has pre-negotiated rates at partner serviced apartments and hotels adjacent to our affiliated hospitals in Mumbai, Delhi, Chennai, Hyderabad, Bangalore (India) and Dubai, Abu Dhabi (UAE)
• Accommodation for one patient attendant/caregiver is included in GAF Healthcare's standard package quotation
• All accommodations are vetted for proximity to the hospital (<10 minutes), accessibility, dietary accommodation (including halal, vegetarian, and medically prescribed diets), and 24-hour front desk support
INTERPRETATION & COMMUNICATION:
• Dedicated medical interpreters and patient coordinators fluent in Arabic, Russian, French, Swahili, Bengali, Uzbek, and other major source-country languages are assigned to each case
• All key medical documents — discharge summaries, pathology reports, operative notes, and adjuvant therapy plans — are translated into the patient's preferred language before departure
• A named GAF Healthcare case manager (available via WhatsApp, email, and phone) serves as the single point of contact throughout the patient's entire treatment journey
FINANCIAL COORDINATION:
• Transparent, itemized cost estimates provided before travel with no hidden fees
• GAF Healthcare facilitates direct billing arrangements with partner hospitals where possible, and provides detailed invoices for insurance reimbursement claims
• Assistance with international insurance pre-authorization and claims documentation
POST-TREATMENT CONTINUITY OF CARE:
• Structured telemedicine follow-up schedule established before the patient's departure
• Remote pathology review, imaging interpretation, and oncology second-opinion services available via GAF Healthcare's network for ongoing decision-making after the patient returns home
Patients Also Explore
Other treatments commonly sought by patients considering Breast Cancer Treatment.
Cryosurgery
Surgical Oncology
Robotic Surgery
Surgical Oncology
Anemia
Hematology
Leukemia Treatment
Hematology